175 related articles for article (PubMed ID: 6435540)
1. [Enhancing effects on interferon-gamma production by combination of OK-432 and interferon-alpha in patients with head and neck cancer].
Sugiyama M; Morisaki N; Konishi K; Go K; Sugita M; Nakai Y
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2200-6. PubMed ID: 6435540
[TBL] [Abstract][Full Text] [Related]
2. [Antitumor effect of OK-432 (1)--antitumor effect of OK-432 induced interferon-gamma (IFN gamma)].
Saito M; Yamaguchi T; Aonuma E; Noda T; Edina T; Ishida N
Gan To Kagaku Ryoho; 1982 Nov; 9(11):2031-7. PubMed ID: 6820888
[TBL] [Abstract][Full Text] [Related]
3. [OK 432-induced production of IFN-gamma in peripheral mononuclear cells from healthy subjects and patients with cancer].
Matsumoto H; Izutani R; Terada M; Noguchi J; Shiraha S; Kuyama T; Aoki N
Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):751-8. PubMed ID: 2506311
[TBL] [Abstract][Full Text] [Related]
4. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
5. Production of tumor necrosis factor (TNF) by monocytes from cancer patients and healthy subjects induced by OK-432 in vitro, and its augmentation by human interferon gamma.
Sekimoto M; Kokunai I; Shimano T; Kobayashi T; Takeda T; Haruna N; Yamamoto A; Mori T
J Clin Lab Immunol; 1988 Nov; 27(3):115-20. PubMed ID: 3150012
[TBL] [Abstract][Full Text] [Related]
6. Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin.
Satoh M; Inagawa H; Shimada Y; Soma G; Oshima H; Mizuno D
J Biol Response Mod; 1987 Oct; 6(5):512-24. PubMed ID: 2445926
[TBL] [Abstract][Full Text] [Related]
7. Enhanced production of gamma-interferon by therapy with parenteral OK-432 and alpha-interferon in patients with head and neck cancer.
Sugiyama M; Yamane H; Cho JS; Okada H; Sugita M; Nakai Y
Arch Otorhinolaryngol; 1986; 243(5):281-7. PubMed ID: 3101655
[TBL] [Abstract][Full Text] [Related]
8. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
Ujiie T
Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
[TBL] [Abstract][Full Text] [Related]
9. [Sequential combination therapy with alpha interferon and OK-432 (streptococcal preparation) against advanced renal cell carcinoma].
Marumo K; Mura M; Deguchi N; Baba S; Jitsukawa S; Nakazono M; Tazaki H
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2434-9. PubMed ID: 3729498
[TBL] [Abstract][Full Text] [Related]
10. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
[TBL] [Abstract][Full Text] [Related]
11. A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells.
Morisaki T; Matsunaga H; Beppu K; Ihara E; Hirano K; Kanaide H; Mori M; Katano M
Anticancer Res; 2000; 20(5B):3363-73. PubMed ID: 11131636
[TBL] [Abstract][Full Text] [Related]
12. [Immunobiological studies of interferon-alpha A/D in comparison with a streptococcal preparation, OK-432].
Mizushima Y; Hirata H; Sakamoto K; Sato M; Morikage T; Maruyama M; Sasaki K; Yano S
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2710-5. PubMed ID: 3631971
[TBL] [Abstract][Full Text] [Related]
13. Priming effect of interferons and interleukin 2 on endogenous production of tumor necrosis factor in mice.
Satoh M; Shimada Y; Inagawa H; Minagawa H; Kajikawa T; Oshima H; Abe S; Yamazaki M; Mizuno D
Jpn J Cancer Res; 1986 Apr; 77(4):342-4. PubMed ID: 2422147
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.
Homma S; Sagawa Y; Komita H; Koido S; Nagasaki E; Ryoma Y; Okamoto M
Cancer Immunol Immunother; 2007 Aug; 56(8):1265-74. PubMed ID: 17219148
[TBL] [Abstract][Full Text] [Related]
15. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state.
Fujimoto T; Duda RB; Szilvasi A; Chen X; Mai M; O'Donnell MA
J Immunol; 1997 Jun; 158(12):5619-26. PubMed ID: 9190909
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha in serum and carcinomatous pleural effusion after repeated intrapleural injections of antitumor agents.
Kaneto E; Sasaki H; Tamura I; Kurimura O; Kurimura T
Biken J; 1983 Jun; 26(2):99-102. PubMed ID: 6318725
[TBL] [Abstract][Full Text] [Related]
18. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432.
Okamoto M; Oshikawa T; Tano T; Ohe G; Furuichi S; Nishikawa H; Ahmed SU; Akashi S; Miyake K; Takeuchi O; Akira S; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
J Natl Cancer Inst; 2003 Feb; 95(4):316-26. PubMed ID: 12591988
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
Oshikawa T; Okamoto M; Ohe G; Furuichi S; Nishikawa H; Uddin Ahmed S; Yoshida H; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
Int Immunopharmacol; 2003 May; 3(5):643-55. PubMed ID: 12757734
[TBL] [Abstract][Full Text] [Related]
20. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
